Biotech Values

[DewDiligence]

Re: Branded generics in emerging markets

ABT’s 2Q11 sales of branded generics in emerging markets grew 25% YoY to an annualized rate of $3.1B. ABT’s 2Q11 overall sales of drugs and devices in emerging markets grew 26% YoY to an annualized rate of $10.4B.

As previously noted in #msg-65328425, NVS’ 2Q11 sales (branded + generic) grew 36% and 20% YoY, respectively, in China and India. (NVS does not disclose sales numbers or growth rates for emerging markets in the aggregate.)